Antitrust Antitrust

GSK's pay-for-delay judgment could mark 'end of an era' for antitrust enforcers, EU official says

By Michael Acton
  • 05 Mar 2020 06:41
  • 05 Mar 2020 06:41
GSK’s pay-for-delay judgment — handed down by judges at the EU’s top court earlier this year — may be the “end of an era” for the EU’s antitrust regulator, allowing it to refocus enforcement efforts elsewhere in the pharmaceutical sector, an EU competition official has said.
"For the past decade we have

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Michael Acton

Senior Correspondent

Michael is a senior correspondent for MLex in San Francisco, where he moved in 2020 after working in our Brussels bureau. Before joining MLex, he reported on EU politics as the Financial Times’ Nico Colchester Fellow in Brussels. Michael has a degree in International Relations and Politics from the University of Cambridge, and a degree in History and French from University College London and Paris IV Sorbonne.

Discover MLex

Stay on top of global regulatory developments

Latest News